Endovascular treatmenT for Acute Ischemic Stroke in China

Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04752735

Acronym

DETECT-China

Enrollment

1000

Registered

2021-02-12

Start date

2021-03-22

Completion date

2023-02-08

Last updated

2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endovascular Treatment, Stroke

Brief summary

This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.

Interventions

OTHERendovascular treatment

all enrolled patients must receive endovascular treatment.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age: ≥ 18; * Ischemic stroke confirmed by head CT or MRI; * Patients receiving endovascular treatment; * First ever stroke or mRS≤2 after previous disease; * Complete and clear pre- and post-operative DSA images are available

Exclusion criteria

* Imaging data not qualified for evaluation; * Absence of important clinical data; * The first 50 patients receiving endovascular treatment in a single centerr.

Design outcomes

Primary

Measure	Time frame	Description
Proportion of patients with modified Rankin Score (mRS) 0 to 2	Day 90	the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

Secondary

Measure	Time frame	Description
Changes in cerebral edema	48 hours, 7 days	edema is determined by middle shift.
Changes in National Institute of Health stroke scale (NIHSS)	Day 2, 7, 14	the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome
Proportion of patients with modified Rankin Score 0 to 2	Day180, 360	Proportion of patients with modified Rankin Score 0 to 2
Proportion of death	Day 7	death due to any cause
Proportion of symptomatic intracranial hemorrhage (sICH)	48 hours	sICH was defined as 4 or more increase in NIHSS caused by hemorrhage
Proportion of intraparenchymal hemorrhage (PH1 and PH2)	48 hours	Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment
Distribution of modified Rankin Score	Day 90, 180, 360	Distribution of modified Rankin Score after treatment

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026